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ABSTRACT
We have compiled the p73-mediated cell cycle
arrest and apoptosis pathways. p73 is a member
of the p53 family, consisting of p53, p63 and p73.
p73 exists in several isoforms, presenting different
domain structures. p73 functions not only as a
tumor suppressor in apoptosis but also as differen-
tiator in embryo development. p53 mutations are
responsible for half of the human cancers; p73 can
partially substitute mutant p53 as tumor suppressor.
The pathways we assembled create a p73-centered
network consisting of 53 proteins and 176 interac-
tions. We clustered our network into five functional
categories: Upregulation, Activation, Suppression,
Transcriptional Activity and Degradation. Our litera-
ture searches led to discovering proteins (c-Jun and
pRb) with apparent opposing functional effects;
these indicate either currently missing proteins
and interactions or experimental misidentification
or functional annotation. For convenience, here we
present the p73 network using the molecular inter-
action map (MIM) notation. The p73 MIM is unique
amongst MIMs, since it further implements detailed
domain features. We highlight shared pathways
between p53 and p73. We expect that the compiled
and organized network would be useful to p53
family-based studies.
INTRODUCTION
p73 is a tumor suppressor protein. It is amember of the p53
familythatiscomposedofp53,p63andp73(1,2).p53isthe
most well-known tumor suppressor and has been suggested
to be mutated in over half of the human cancers (3). It was
thought to be the only member of the family until p73 was
discovered in 1997 (4). In addition to the p73’s tumor
suppression task, p63 and p73 play roles in the develop-
ment at the embryonic stage, particularly of the limb,
epithelial, craniofacial, neuronal and pheromonal, respec-
tively (5–7). The availability of data relating to the interac-
tions with p73 should be useful in drug discovery (8,9).
All p53 family members display similar domain struc-
tures, having an N-terminal transactivation (TA) domain,
a DNA-binding domain (DBD) and an oligomerization
domain (OD). p73 and p63 share a sterile alpha motif
domain (SAM) and an inhibitory domain (ID) at their
C-termini. In addition to the similarity in the domain
structures, p73 and p63 have a higher sequence homology
as compared with p53. It has been further suggested that
all family members have evolved from a p63/p73-like
ancestral gene, which can be supported by the existence
of SAM domain in squid p53 (1,4,10). The hierarchical
evolution tree of the family also places p53at the
bottom, suggesting p53 as the newly evolved gene
among the family members (2). p53, p63 and p73 share
a high sequence similarity, especially in their DBD’s. The
homology between p73 and p53 is 29% in the TA domain,
63% in the DBD and 38% in the OD (11). Consequently,
family members have common target genes, e.g. p21 (4,12)
as well as their unique targets such as CaN19 for p73 (13).
Both p53 and p73 are tumor suppressors, while p63 and
p73 play a role in tissue diﬀerentiation. All three proteins
form a complex network, which can be of signiﬁcance in
cancer formation, and p53 requires both p73 and p63 for
proper function (14,15). However, how this complex
mechanism is regulated is still unknown. Given that p53
is the most widely studied, we focus on p73 and its rela-
tionship with p53.
Despite high functional and sequential similarity, the
p73 promoter does not share homology with the p53 pro-
moter (16) and again unlike p53, p73 is rarely mutated in
human cancers (17). p73 knockout mutants do not show
rapid tumor formation; instead, some defects in normal
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ﬁed for p73 as compared with p53; g-IR and some che-
motherapeutic drugs, such as cisplatin lead to p73-induced
cell death (1). Several p73 isoforms are encoded with
C- and/or N-terminus truncations. Dimers and tetramers
can be formed not only among isoforms of p73, but also
among the family members, p73 and p53. The aﬃnities for
the formation of hetero-oligomers are lower than of
homo-oligomers in p73 (18). Both wild-type and some of
the mutant p53 forms can be involved in hetero-tetramer
formation (19,20).
There are seven C-terminus truncation types in p73,
some of which are tissue speciﬁc (20,21). N-terminus trun-
cated isoforms are formed by an alternate promoter in
intron 3 (7) and they can have C-terminus truncations
regardless of the N-terminus status (Figure 1). If a trunca-
tion occurs at the N terminus, the protein is labeled as
Np73; otherwise as TAp73. N isoforms lack the TA
domain and their TA activity is signiﬁcantly reduced.
Having the same domain structure as TAp73 apart from
the absence of the TA domain, Np73 can oligomerize
with p53 and p73. Np73 can also compete for binding to
target the DNA sites of these proteins. Thus, Np73 has
an inhibitory eﬀect on p53 and p73, at the oligomerization
and the DNA-binding levels (7,20). Interestingly, it was
also observed that p53 and TAp73 induced TA of
Np73, forming a negative feedback loop (22). It is also
known that Np73 is overexpressed in human cancers
(23). The ratio between the N and TA isoforms, rather
than the p73 mutations, is the key factor in the determina-
tion of cell fate (17,22).
To further clarify the tumor suppression activity
mediated by p73, we compiled its interactions which
govern p73 regulation and function. We assembled and
analyzed the network that centers on p73. To better orga-
nize and disseminate the data, we represented the network
in MIM format. A brief comparison with the interaction
network of p53 (24), is also made.
MATERIALS AND METHODS
Data compilation
Several databases (DIP, STRING, Biocarta, e-MIM,
DOQCS, Biopax, Bind, Patika, Puma2, Biocyc,
Mpact, Transpath, Predictome, Indigo, MINT, HPRD,
BioGRID) of protein–protein interactions (PPI) and pro-
tein interaction networks are scanned for interactions of
p73. In addition, a detailed literature search on article
databases has been carried out, independent of the results
obtained at the ﬁrst step. This data compilation process is
until August 2007. The interactions are veriﬁed by more
than one independent source, where available, before
being incorporated into the map. The independent sources
could either be two articles that do not take the informa-
tion from the same reference or one interaction database
and one article. In those cases where the interaction pre-
sented in the article is validated through a small-scale
experiment such as yeast two-hybrid or aﬃnity puriﬁca-
tion, one reference was taken as suﬃcient. However, if the
interaction obtained from a single reference is produced as
a result of a large-scale experiment, the information was
not incorporated into the map, since high-throughput
data does not necessarily point out to a real physical asso-
ciation. We also looked for additional support before
incorporating the single cited interactions into the net-
work. Based on the supportive information, single refer-
enced nodes can be classiﬁed into three categories: (i)
proteins with available information related to speciﬁc
binding sites; this could indicate an assurance of the exis-
tence of binding interaction (e.g. Itch in D6); (ii) proteins
that are cited as part of the p53 network (e.g. c-Jun in
A53), which may suggest that they also have a function
in p73 network and (iii) proteins whose interaction sites
are known and are also cited as existing in the p53 net-
work (e.g. Chk1 in A31).
When contradictory information was encountered, the
publication years and sources were compared. Under such
circumstances, a more detailed search on these proteins
has been performed by investigating their properties and
interactions apart from the pathways related to p73 func-
tion. The decision as to the incorporation of the interac-
tions has been reached only after this detailed analysis
was made.
PPI network diagrams
Network diagrams can be classiﬁed into three main cate-
gories: explicit, heuristic and combinatorially complex.
Heuristic and combinatorial diagrams can display large
networks in a compact form, covering all possible
Figure 1. Isoforms of p73. The longest p73 isoform is TAP73a. Partial or full domains may be missing in the isoforms with N- and/or C-terminus
truncations.
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other hand, explicit diagrams include also the directed and
sequential relationships of the pathways (25). Thus, heu-
ristic and combinatorial diagrams can present the logic of
the network in a human-readable format, while explicit
diagrams are more suitable for computer simulations (26).
Several notations have been proposed for the represen-
tation of processes in interaction networks. Two well-
known notations are the molecular interaction maps
(MIM), proposed by Kohn and coworkers (24,27) and
process diagrams, proposed by Kitano et al. (28,29).
While being able to represent explicit diagrams, the
MIM notation is prepared mainly for construction of
heuristic and combinatorially complex diagrams (26). On
the other hand, process diagrams are generally used for
the construction of explicit diagrams (25). Detailed com-
parisons of notations can be found in the literature
(25,30). Considering the number and characteristics of
p73 interactions, we have decided to use the MIM nota-
tions for the representation of the p73 interaction
network.
MIM notation and symbols
In a MIM each species is represented at one place only.
The interactions, complexes and eﬀects of the proteins or
interactions are represented using deﬁned symbols. In the
MIM notation, the symbols representing the interactions
are mainly grouped into two types, reaction symbols and
contingency symbols (Figure 2b). By classifying the rela-
tions among nodes (proteins or promoters), the reaction
symbols deﬁne physical interactions, protein complexes,
covalent binding and other such events. Contingencies
represent eﬀects like inhibition and stimulation (25),
which may emerge from and be directed to nodes or
edges (reactions or contingencies of the MIM). The nota-
tion of MIM can be found in the literature together with
examples (27).
Extensions made on theKohn notation
The domain representation that is already available in the
Kohn notation (24) has been extended by a line, which is
drawn above the node, representing the whole protein,
regardless of the domains. The distinction between the
interactions known to take place between speciﬁc domains
of the involved protein, and interactions without such
available detailed information, is incorporated into the
map (Figure 3). Interaction number 1 is speciﬁc to
domain 1, but interaction number 2 implies no currently
known domain speciﬁcity. Therefore, an isoform lacking
domain 1 will not have interaction 1, whereas the status of
interaction 2 is unknown, since the place of the binding
site involved in the interaction is not known.
As discussed in the Introduction section, the ratio
among N and TA isoforms is the key factor in cancer
research on p73 (17,22). Thus, it is reasonable to represent
the N and TA isoforms separately on the p73 MIM.
Almost all interactions are common for the N and TA
isoforms except for the ones taking part through the TA
domain. These common interactions are not shown on the
N isoform to avoid redundancy.
Assessment ofdata
The nodes of p73 MIM are grouped into functional cate-
gories, and the interactions are labeled accordingly. Each
label is a combination of a letter, representing the category
interaction it is associated with, and a number. While
there is no such restriction, in most cases the numerical
sequence of interaction labels represent the occurrence of
interactions on the pathways (see Table 3, Annotations).
In the majority of the publications aiming to test the
p73 activity level, the transcription levels of one selected
protein, mostly p21, is measured experimentally and the
eﬀect is stated as transcriptional activation or inhibition of
p73. Unless stated otherwise, these eﬀects are accepted as
related to transcriptional activation of all target promoters
(combined promoter). Mapping it on the p73 MIM, the
stimulation or inhibition eﬀect is directed to the interac-
tion labeled ‘A29’.
Clustering
In agglomerative hierarchical clustering, the clustering
starts at the binary level and attempts to get higher
degree clusters until a united cluster is obtained (31).
The main criterion of the algorithm is the distance
between the members. The nearer the members are, the
higher the probability that they will get under the same
tree branch. Keeping the distance measure constant,
groups are constructed according to three norms: single-
link (farthest neighbor), complete-link (nearest neighbor)
and average-link. In single-link clustering, the distance is
designated as the smallest; in complete-link as the largest;
and in average-link as the mean distance between the clus-
tered elements of each iteration (31).
The input for the clustering algorithm was a connectiv-
ity matrix (CM). CM is binary, square and its dimension is
n   n, where n is the number of the nodes in the network.
Each element (i,j) of the CM corresponds to the availabil-
ity of an interaction between any proteins in the network.
The interacting nodes are recorded as CM (i,j)=1 and
noninteracting nodes as CM (i,j)= 0.
For clustering purposes, the tool EXpression Analyzer
and DisplayER (EXPANDER) is used (32). Average-link
agglomerative hierarchical clustering is employed with a
distance expression inversely related to the Pearson corre-
lation coeﬃcient.
RESULTS
MIMof p73 isaheuristic MIM constructed forp73
mediated cell cycle arrest and apoptosis
Using the MIM notations proposed by Kohn et al. (27)
with the additional notations including the extended
domain representation, distinct representation of isoforms
(see Materials and methods section), and organizing the
information related to the interactions, the p73 MIM is
constructed. At the data gathering stage only the interac-
tions which are directly or indirectly related to the func-
tion of p73 in cell cycle arrest and apoptosis are taken into
account. The interactions of p73 related to its role in dif-
ferentiation are excluded from the map. For ease of use in
Nucleic Acids Research, 2008, Vol. 36, No. 15 5035Figure 2. MIM of p73. A softcopy of the MIM of p73 can be downloaded from ‘http://www.prc.boun.edu.tr/PRC/software.html’. (a) The MIM of
the p73 protein, including the interactions related to cell cycle arrest and apoptosis mediated by p73. The interactions are grouped into functional
categories, and each interaction is labeled accordingly. The details of each interaction can be found in Table 3, which includes the Annotations.
(b) The list of symbols used in the representation of the interactions, i.e. the MIM Symbols (24). (c) The schematic representation of p73 MIM,
highlighting the functional categories on the map.
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Nucleic Acids Research, 2008, Vol. 36, No. 15 5037future studies, the interaction information is stored in
both computer readable (using Systems Biology Markup
Language) and human readable formats.
In the p73 MIM, p73 is placed at the center of the map.
The interactions are organized around the p73 node, with-
out time and space constraints. The diverse roles of the
p73 domains in the p73 functions are presented in detail.
All interactions are directed to the relevant domain when
information is available. The resulting p73 MIM consists
of 53 nodes (proteins) and 176 edges (physical interactions
or functional relations) (Figure 2a). In addition to the
nodes and edges, the p73 MIM also contains several pro-
moters and deﬁnition boxes. The boxes represent states or
events, such as DNA damage or degradation. The p73
MIM includes only end points of some pathways, where
the leading path is not directly related to p73 function,
such as cleaved PKCd, PKCdCF. We excluded the details
of each box and such pathways, since they are beyond the
scope of this work. The proteins represented as nodes of
the p73 MIM may have interactions other than those dis-
played in the map, related to their individual functions
which are apart from p73 mediated apoptosis.
A list of proteins represented in the map with their
accession codes is also provided (Supplementary
Table 1). A softcopy of the MIM of p73 can be
downloaded from http://www.prc.boun.edu.tr/PRC/
software.html.
Proteins ofp73 MIM aregrouped into functional categories
The proteins involved in the p73 MIM are grouped into
functional categories, according to their eﬀects on the net-
work (Table 1). The deﬁned categories are Upregulation,
Activation, Suppression, Degradation, and Transcriptional
Activation. A protein may have roles in more than one
pathway, belonging to diﬀerent functional categories. In
such cases, the protein is located in a category according
to its major function based on current literature. However
p73, its N isoform and pRB could not be assigned to a
single functional category and are represented as separate
nodes, since their roles are critical in several paths. The
edges are labeled according to functional categories so
that the letters used in the labels of the edges are the
initials of their related categories (see Materials and meth-
ods section). The details of all interactions and their cor-
responding references can be found at the end of the
article, in the Annotations (Table 3). The Annotations
are organized with respect to the deﬁned categories and
the labels of the edges.
In the related Results section, we investigated the fol-
lowing characteristics of each functional category: (i) the
number of members of each category; (ii) important nodes
which are assigned to each category and (iii) interrelation-
ships between members of diﬀerent categories.
Table 1. Proteins of the p73 MIM grouped into functional categories
Functional categories
Upregulation Activation Suppression Degradation Transcriptional activation
E2F1 (B:1) Pin-1 (D:4) RACK1 (D:8) Cyclin G (I:10) hTERT (I:3)
Chk2 (B:2) c-Jun (B:7) MDM2 (B:8) Ubc-9 (I:10) Apaf-1 (I:3)
TGFb (D:1) ASPP1/2 (D:6) MDMX (B:9) Cullin (J:8) PUMA (I:4)
ZEB (C:1) p38 (D:4) CTF2 (C:10) Itch (I:8) Bax (I:4)
Tax (C:2) PML (E:4) WT1 (D:10) NQO1 (J:10) Scotin (I:4)
E1A (D:2) MM1 (C:6) SIRT1 (D:8) UFD2a (J:10) p21 (H:4)
c-Abl (C:4) E4orf6 (C:10) Roc1 (J:9) GADD45 (H:4)
YAP (C:7) Akt (C:8) 14-3-3s (I:4)
p300/CBP (D:5) PIAS-1 (E:8) IGF-BP3 (I:4)
Chk1 (C:5) Daxx (C:8) GADD 153/CHOP (I:4)
Ungrouped p19
ras (C:7) Amphiphysin IIb-1 (C:10) Noxa (I:4)
pRB (D:3) PKCdCF (C:6) Wwox (B:10) Killer/DR5 (H:4)
p73 (G:5-9) ATM (C:4) Cyclin A/B:CDK1/2 (D:9) PIG3 (H:4)
Np73 (G:2) ATR (C:5) PKA-Cb (D:10) CD95 (H:4)
PMS2 (D:6) Pirh2 (D:10) p53AIP1 (I:4)
NEDL2 (B:6) p53R2 (H:4)
HIPK2 (C:6)
PML-NB (D:5)
Figure 3. Extended domain representation. The extension made on
MIM notation for interactions acting on the same protein, depending
on the availability of information on domains; (1) an interaction
occurring speciﬁcally through domain 1 of the protein is directed to
this domain; (2) is a known interaction of the protein without available
information on which domains are aﬀected. Here the interaction line,
arrow 2, is directed to the line drawn above the node, thus representing
the whole protein.
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The Upregulation category contains the nodes and edges
that are related to the transcription of the p73. In this
category, there are 6 nodes, 24 edges and 3 promoters.
This group is directly related to the Activation category,
since both categories are essential for p73 function. The
key node of this unit is E2F1 which has the highest
number of interactions and is of crucial biological impor-
tance in the activation of the p73 promoter. E2F1 is a
transcription factor which controls the progression of
the cell-cycle from the G1 to the S phase. E2F1 is activated
via phosphorylation (U7; see label U7 in the Map and its
details in the Annotations, Table 3). Active E2F1 can
stimulate either cell cycle arrest or apoptosis, as in the
case of the DNA damage. By enhancing the activity of
ATM on Chk2 (labels U2, U11), E2F1 forms a positive
feedback loop, where ATM activates Chk2 and Chk2
further increases the activity of E2F1 by phosphorylation.
Additionally, E2F1 can bind to either p73 (U9) or the
Apaf-1 promoter (T6) to stimulate the transcription of
p73 and Apaf-1 (U10, T8). Furthermore, the activity of
E2F1 is inhibited when it forms a complex with pRB.
Under such circumstances, the concentration of E2F1 is
regulated by pRB (U17–18).
There are controversial data in the literature regarding
the viral oncogene E1A. According to some sources, E1A
hinders the activation of p73 (33). In contrast, other stu-
dies (34) point out that E1A can activate p73, by binding
to pRB and thus releasing E2F1. Following a comprehen-
sive literature search, examining the sources of the argu-
ments, and the dates of the relevant publications, it
appears to us that E1A plays a role in the activation
of p73 (U21–22). Consequently, only this aspect of the
behavior of E1A is mapped on the p73 MIM.
The Activation and Suppression functional categories
The Activation and Suppression categories can be grouped
under the same heading, since the nodes (proteins) belong-
ing to those categories function by modifying p73at the
posttranscriptional level.
The nodes included in the Activation functional cate-
gory are related to the posttranscriptional activation of
the p73 protein. This category consists of 18 nodes, 2
promoters and 59 edges. Within this category DNA
damage is represented by a box. p73 is activated when
DNA damage results as an outcome of g-IR or some che-
motherapeutic drug (1). The main activation pathway of
p73 is the signaling cascade initiated by the recognition
of the damaged DNA by ATM (A3). After the activation
of ATM, it activates c-Abl by phosphorylation (A8–10).
c-Abl binds to the PXXP motif of p73 (A12) and causes its
phosphorylation at the tyrosine (Y99) (A14) and threo-
nine (A16) residues, directly and by activating p38, respec-
tively. Phosphorylated p73 is recognized by Pin-1
isomerase with a consequent conformational change of
p73. In the next step, p73 is recruited to PML-NBs
where it is acetylated by p300/CBP and becomes fully
active (A21, A25–27). In addition to the main pathway,
there are several proteins which can lead to an increase in
the activity of p73 either by direct binding or via posttran-
scriptional modiﬁcations.
The Suppression functional category contains 15 nodes,
one promoter and 54 edges, which are related to the sup-
pression of p73 function. The most important node in this
category is MDM2, which is also a crucial node in the p53
network. MDM2 leads to the inactivation of p73, but does
not degrade it. In addition, the MDM2 promoter is acti-
vated by p73, forming a negative feedback loop. Most of
the proteins involved in p73 suppression are p73’s ﬁrst-
degree interactions. The inhibitory eﬀects of p73 SAM and
ID domains, on the p73 protein itself are also assigned to
the Suppression functional category (S41).
The Activation and Suppression functional categories
are interrelated through few direct interactions, as can
be seen from the p73 MIM. (Figure 2a) The functional
relationship between these categories occurs largely at
two successive steps, such that a member of one category
blocks the eﬀect of a member of the other, through p73.
The Activation functional category is interrelated to the
Upregulation by ﬁrst-degree interactions, with a larger
number of direct interactions as compared with the
Suppression category.
The Degradationfunctional category
This category contains the nodes that are related to the
degradation of p73. In this category, there are 7 nodes,
1 promoter and 22 edges. Among these seven, three regu-
late the ‘standard’ degradation mechanism via ubiquiti-
nation (D6–9, 11–14); one by sumoylation (D4–5, S22);
three by forming a complex with p73 (D15–20).
Neddylated Cullin:Roc1 complex (D10–11) constitutes
the core module of E3 ubiquitin ligase. The formation of
the module stimulates the ubiquitination of p73 resulting
in the proteasomal degradation of p73 (D12–14). In a
similar manner, another ligase Itch, promotes an increase
in the ubiquitination level of p73 (D6–9). Other than
these, the SUMO conjugating enzyme, Ubc9 stimulates
the sumoylation of p73at the C-terminus (D4–5, S22).
This is another way for p73 to be ﬂagged for rapid degra-
dation. Additionally, there is a negative feedback loop
between p73 and Cyclin G. p73 stimulates the transcrip-
tion of Cyclin G, while Cyclin G enhances its degradation
(D19–22).
The nodes involved in this category exert their eﬀects on
p73 directly, without forming complex paths. There are no
direct interrelationships with other categories.
The Transcriptional Activation functionalcategory
The Transcriptional Activation category contains 6 nodes, 3
promoters, 17 edges and an Apoptosis box. In this func-
tional category, the promoters which are activated by p73
are represented by one combined promoter (T1, T2) (see
Materials and methods section). Currently available data
on the interactions between p73 and speciﬁc promoters are
provided in the Annotations (Table 3). If the edges directed
to T1 are traced in the map, speciﬁc information about
each promoter can be reached through the Annotations.
Following TA of the promoters by p73, the translated
proteins can promote cell cycle arrest and apoptosis.
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tion are not included in the list, since in principle the map
is constructed for apoptosis. If a promoter is signiﬁcant in
the p73 MIM, other than being a target of p73, such as
MDM2 promoter, then it is also represented in other rele-
vant categories (e.g. S10). Other than the activated pro-
moters, the apoptosis pathway that is induced by Bax and
PUMA proteins (T9–10) and the inhibition of hTert tran-
scription (T3–5) are of importance in this category. In the
apoptosis pathway, PUMA and Bax are transcribed by
p73 (T2). After being transcribed, PUMA causes confor-
mational change of Bax, and induces its translocation
inside the mitochondria (T9). Once Bax is located in the
mitochondria, it causes cytochrome c release. Binding
of Apaf-1 to the released cytochrome c leads to the for-
mation of the caspase cascade and eventually apoptosis
(T12–15). The hTert upregulation is a well-known cause
of the maintenance of the telomerase length in most of
human cancers. The binding of p73–Sp1 (T6), leads to
inhibition of the hTERT transcription; thus is also impor-
tant in the p73 mediated tumor suppression.
The interrelation of this category with other categories
is limited to the interaction of p73 with promoters (T1)
and activation of speciﬁc promoters by E2F1 (T3/6).
The MIMof p73 includes anticoherent interactions
To be preferred by evolution, the function of a protein
should provide robustness to the cell. And mechanisms
involved in a robust biological network should be regu-
lated in a coherent manner to maintain homeostasis at any
level of an organism (28). Therefore, if a speciﬁc form of a
protein is a positive regulator of a particular event in one
path, then its eﬀect via other paths toward that outcome
should also be positive. Similarly, a negative regulator
should have negative eﬀects on the same node through
diﬀerent interactions. In the literature, interactions of a
protein may be stated to lead to opposing end points by
using diﬀerent paths. In such cases, the node is deﬁned as
anticoherent. When related edges of each node are tracked
on the p73 MIM, two important proteins can be deter-
mined as anticoherent nodes of the system. These proteins
are pRB, which is not assigned to any functional category,
and c-Jun in The Activation and Suppression functional
categories.
The activity of E2F1, which is discussed in detail
under The Upregulation functional category section, is
suppressed when E2F1 forms a complex with pRB
(U17–18). With this interaction, pRB has a negative
eﬀect on the p73 activity. However, binding of pRB to
RACK1 (S17) appears to have a positive eﬀect on p73.
RACK1 is a repressor of p73; when there is a physical
interaction between p73 and RACK1, the p73 transcrip-
tional activity is inhibited (S15–16). The pRB interaction
with RACK1 frees the p73 from repression (S18). These
two opposing actions suggest that pRB is an anticoherent
node in the p73 tumor suppression network.
c-Jun appears to be a positive regulator of p73. It inhi-
bits p73 degradation (D3) and stimulates p73 transcrip-
tional activity (A53). On the other hand, c-Jun also binds
to the MDM2 promoter and enhances its transcription
(S8, S10). As mentioned in The Activation and
Suppression functional categories section, MDM2 sup-
presses the p73 activity. These two opposing actions indi-
cate that c-Jun is an anticoherent node in the p73 network.
Interestingly, there is a direct relationship between those
two anticoherent proteins. pRB binds to the c-Jun promo-
ter and stimulates its transcription (A57–58).
The p73 MIM andthe network of p53share proteins with
similar and opposingroles
A good starting point to understand the logic of the p73
tumor suppression mechanism would be a comparison
between the p53 and p73 networks. The common and
distinct features of the p53 and p73 networks may describe
parallel or diverse functions of these tumor suppressors.
Expression of the compared features of both p53 and p73
networks in the p73 MIM would require implementation
of the p53 protein and p53 related pathways into the
MIM. Such an implementation would cause divergence
from the focus on p73 interactions in cell cycle and apop-
tosis in the MIM. Therefore, a brief comparison among
the nodes in the p73 MIM and the members of the p53
network is made. For this purpose, a preexisting p53 MIM
(24) and the data obtained from the literature are used.
Among the compared nodes, 12 proteins (ATM, p300,
Cyclin A/Cdk2, HIPK2, Chk1, Chk2, p21, 14–3–3s,
Gadd45, Bax, PUMA, Cyclin G) function in the same
manner or lead to similar eﬀects using diﬀerent mecha-
nisms, 2 (MDM2, c-Abl) have diﬀerent roles and two
nodes (c-Jun, CTF2) have diverse end eﬀects on p53 and
p73. A summary of the comparison is given in Table 2.
Following the interactions of ATM in the p53 network
and the p73 MIM, it can be seen that ATM directly acti-
vates p53 by phosphorylation at Ser15 (35) and leads to
activation of p73 indirectly (36), (A8). Pin1 imposes a
conformational change on p73 and p53 (A17) (17). p300
binds to the TA domains of p53 and p73, to enhance their
functional activities (24,37), (A23). Cyclin A/Cdk2 can
phosphorylate p53 and p73 (38,17), (S43). Serine/threo-
nine kinase HIPK2 physically interacts with the ODs of
Table 2. The role in the p73 MIM and the p53 network for the proteins
with available information
Protein Eﬀect Mechanism References
ATM Same Diﬀerent (35,36,64,65)
c-Abl Diﬀerent – (24,44,69)
Chk1 Same Same (40)
Chk2 Same Diﬀerent (40)
c-jun Opposing – (45)
CTF2 Opposing – (46,78)
CyclinA/Cdk2 Same Same (17,38,102)
Cyclin G Same Diﬀerent (117)
E4orf6 No int. w/p53 – (48,96,98)
HIPK2 Same Same (39)
Itch No int. w/p53 – (47,113)
MDM2 Diﬀerent – (42,43,89)
MM1 No int. w/p53 – (45,80)
NEDL2 No int. w/p53 – (47,83)
p300 Same Same (24,37,73,74)
Pin1 Same Same (17,67)
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Upregulation
[U1] Chk2 is phosphorylated at Thr68 (50,51).
[U2] ATM induces phosphorylation of Chk2 (50,51).
[U3] [U4] Phosphorylated Chk2 mediates its own dimerization (51,52).
[U5] [U6] Chk2 dimer is activated further by regulating its own autophosphorylation (in trans at residues 383, 387
and 516.) (51,52).
[U7] E2F1 is phosphorylated at its consensus Chk phospohorylation site; Ser364, which results in its activation (40,53).
[U8] Activated Chk2 catalyzes the phosphorylation of E2F1 (40,53).
[U9] [U10] p73 promoter contains E2F1 responsive elements. E2F1 can bind to these elements. But whether it can bind selectively to
the promoter regions of diﬀerent isoforms or it can induce both of them simultaneously is still a controversial
issue (54,53).
[U11] p73 promoter becomes transcriptionally active via E2F1 (54,11).
[U12] E2F1 upregulates Chk2 (51,55).
[U13] Since E2F1 can also stimulate the transcription of Chk2, it can be stated that there is a positive feedback loop among
Chk2 and E2F1 (51,55).
[U14] [U140] [U15] [U16] Tax increases the level of E2F-1 (56).
[U17] pRB directly binds to active E2F1 (57,58).
[U18] Activated E2F1 protein can induce the apoptotic activity of p73. If the cell wants to stay arrested in the cell cycle, pRB
mediates inhibiton of the E2F1 eﬀect on p73 (24,57,59,60).
[U19] If pRB is phosphorylated, its functioning is disturbed (57,58).
[U21 [U22] E1A is a viral protein and it indirectly enhances the upregulation of p73; because it can bind to pRB and inhibit pRB
mediated E2F1 repression (57,61).
[U23] TGFb prevents the phosphorylation of pRB. Thus, it indirectly stimulates the inhibition eﬀect of pRB on E2F1 (54).
[U24] On the intronic fragment, which lies between the promoters of TAp73 and Np73, there are six consensus ZEB-binding
sites. ZEB binding on p73 promoter is a known fact; however, how this protein regulates the amounts of the isoforms
is still a controversial topic (62).
Activation
[A1] [A2] ATM normally exists as an inactive dimer (51,63).
[A3] The conﬁguration of ATM changes as a result of its binding to the damaged DNA (51,63).
[A4] ATM can catalyze its autophosphorylation in trans at Ser1981 (51,63).
[A5] ATM is phosphorylated at Ser1981 (51,63).
[A6] The conﬁgurational change of ATM is required for the stimulation of its autophosphorylation (51,63).
[A7] Phosphorylation of ATM inhibits its dimer formation. In this way, ATM is fully activated (51,63).
[A8] ATM interacts with c-Abl (64,65).
[A9] c-Abl is phosphorylated at Ser465 (64,65).
[A10] The interaction of ATM and c-Abl results in phosphorylation of c-Abl (64,65).
[A11] c-Abl becomes active via its phosphorylation. After its activity is established, it can start the signaling cascade, which
leads to the stabilization and activation of p73. In response to DNA damage, c-abl signaling cascade requires the
following events in sequential order: the phosohorylation of p73 which is mediated by p38; conformational change
of p73 which is induced by Pin1; participation of p73 in PML-NB and acetylation of p73 as a result of its interaction
with p300 (37,66–68).
[A12] c-Abl binds via its SH3 domain to p73’s PXXP motif, which is between residues 322 and 339 (44,69).
[A13] p73 is phosphorylated at Tyr99 (44,69).
[A14] Formation of the p73:c-Abl complex is a requirement for the phosphorylation of p73at its Tyr99 (44,69).
[A15] [A16] p38 mediates the phosphorylation of p73. The phosphorylation sites on are Thr residues adjacent to prolines (66,68).
[A17] To stabilize p73, Pin1 binds to it and induces its conformational change. Pin1-binding sites on p73 are 412,442,482 (67).
[A18] p73 phosphorylation is a requirement for its association with Pin1 (67).
[A19] PML is sumoylated at three lysine residues (70,71).
[A20] PML should be covalently modiﬁed by SUMO-1, to form PML-NB complex (70,72).
[A21] PML-NB binds to p73 and rearranges its half-life (66).
[A22] Pin1 and p73 interaction is a step in the c-abl signaling cascade. The consecutive step after that is the formation of the
PML-NB:p73 (66,67).
[A23] p300/CBP (via its CH1 Domain) interacts with p73 (at its TA Domain) (73,74).
[A24] p73 is acetylated at lysine residues; 321, 327 and 331 (37,66).
[A25] The binding of p300/CBP to p73, stimulates acetylation of p73 (37,66).
[A26] The acetylation of p73 which is mediated by p300/CBP is PML-NB dependent (66).
[A27] [A270] The last step of the c-abl signaling cascade is accomplished by the acetylation of p73, which leads to the enhancement of
p73’s TA activity (37,66,74).
[A28] Chk1 is phosphorylated at Ser317 and Ser345. And this phosphorylation leads to its activation (75,76).
[A29] The phosphorylation of Chk1 is mediated by ATR (75,76).
[A30] p73 is phosphorylated at its TA; at Serine 47 (77).
[A31] Chk1 can regulate the activity of p73 by enhancing its phosphorylation at its TA (40,77).
[A32] Phosphorylation of p73 by Chk1 increases its proapoptotic activity (40,77).
[A33] ASPP1/2 can bind to the DBD of both p73 and p63 (78).
[A34] The binding of ASPP1/2 to p73 stimulates activation of genes; Bax, PUMA, PIG3 (78).
[A35] The physical interaction between PMS2 and p73 stabilizes p73 by increasing its half-life (79).
(continued)
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[A36] The stabilization process of p73, which is mediated by PMS2 results in the induction of apoptosis. And it is claimed that
this process is somehow dependent on c-abl. Basing on this claim, it would be reasonable to propose that PMS2
participates in the c-abl signaling cascade (79).
[A37] MM1 can bind to the C-terminus of p73 (80).
[A38] Binding of MM1 enhances the TA of p73 on Bax and Pig3 (80).
[A39] HIPK2 is modiﬁed by SUMO-1 (81).
[A40] Sumoylated HIPK2 can enter in to PML-NB (81).
[A41] HIPK2 and p73 form complex via their 817–907 and 345–380 residue ranges, respectively (39).
[A42] Formation of p73:HIPK2 increases the apoptotic activity of p73. Since HIPK2 also localized in PML-NB, it would be
logical to hypothesize that the action of HIPK2 is a part of the c-abl signaling cascade (39).
[A43] p73 is phosphorylated at Ser289, which is located at DBD (82).
[A44] PKCdCF stimulates phosphorylation of p73at its DBD, thus increases its activity (82).
[A45] p73:NEDL2 is modulated via p73’s COOH terminal region (PY motif) and WW domain of NEDL2 (83).
[A46] Ubiquitination of p73 results in its stabilization (83).
[A47] NEDL2 regulates the stabilization of p73 by enhancing its ubiquitination (83,84).
[A48] p73 and YAP directly interact via their PPPPY motif and WW domain, respectively (85).
[A49] YAP can enhance the transcriptional activity of p73 by forming p73:YAP complex (85).
[A50] p19ras (via the region between 56 and 87) interacts with p73 (at DBD) (86).
[A51] p19ras can also interact with MDM2 via the same region which is used in its interaction with p73 (86).
[A52] When p19ras: MDM2 complex is formed, MDM2 can not inhibit the activity of p73 anymore (86).
[A53] c-Jun modulates the stability of p73 to stimulate its transcriptional activity. It is proposed that c-Jun aﬀects only
TAp73 isoforms. So, this protein may be one of the selective eﬀectors among p73 isoforms (45).
[A54] [A540] [A55] E2F1 can bind and active the promoter of ASPPs (87).
[A56] [A560] [A57] E1A stimulates the transcription of c-Jun (88).
[A58] [A59] Homo-dimerization and also homo-tetramerization of TAp73 is regulated by OD (4,18).
Suppression
[S1] [S2] Both MDM2 and MDMX bind to p73at its N-terminus; between the residues 1–70 (43,89).
[S3] MDM2/MDMX and p300 share the same binding site on p73. If this speciﬁc site is occupied by MDM2/MDMX, p300
cannot bind to p73 and enhance its TA activity (43,95).
[S4] [S5] MDM2/MDMX competes with p73 for the same binding site on p300, which is located at its N-terminus (43).
[S6] If MDM2/MDMX:p300 complex is formed, p73 can no longer be activated via c-abl signaling cascade (43).
[S7] p73 can activate the promoter of MDM2. So, it would be reasonable to state that the feedback loop among MDM2 and
p73 is negative (41,43).
[S8] MDM2 can also be transactivated by c-Jun (90).
[S9] [S10] The level of MDM2 is upregulated (41,43,90).
[S11] S/P/T-rich C-terminal domain of Daxx, which lies between 667 and 740, can interact with the OD of p73. The interaction
speciﬁc region of p73 is composed of 345–380 residue range (91,92).
[S12] The interaction between Daxx and p73 leads the repression of the p73’s transcriptional activity (91,92).
[S13] Daxx is recruited to PML complex (91–93).
[S14] Via forming a complex with PML, the repression activity of Daxx (on p73) can be relived (91,92).
[S15] RACK1 regulates the activity of p73 by binding to its C-terminus (94).
[S16] RACK1 regulates the activity of p73 negatively (94).
[S17] pRB and RACK1 interacts physically (94).
[S18] RACK1 imposes a transcriptional repression on p73. And this repression can be overcome by the formation of
pRB:RACK1 complex (94).
[S19] SIRT1 and p73 are interacting proteins (95).
[S20] SIRT1 is a NAD-dependent deacetylase. After it binds to p73, it cleaves the acetylations, which have been modulated
by p300. So, if the interaction between SIRT1 and p73 is established, the transcriptional activity of p73 is repressed;
since c-abl mediated signaling cascade cannot survive without having the acetylated p73 residues (95).
[S21] PIAS-1 binds to a, b and g types of p73 isoforms (96,97).
[S22] There is a speciﬁc residue at the extreme C-terminus of p73 (Lys627) for sumoylation. Therefore, only p73a can be
covalently modiﬁed by SUMO-1. The modiﬁcations regulated by SUMO-1 can alter the subcellular localization of p73
but does not eﬀect much its transactivity (96,98).
[S23] PIAS-1 can stimulate sumoylation of p73 (96,98).
[S24] p73 and Wwox interacts via their PPPPY motif and ﬁrst WW domain, respectively (99).
[S25] If p73 forms a complex with Wwox, nuclear p73 is transported to the cytoplasm resulting in its inactivation of p73 (99).
[S26] [S27] Wwox is phosphorylated at Y33 and this phosphorylation enhances its binding to p73 (99).
[S28] By use of the SH3 domain of amphiphysin IIb-1 and C-terminus of p73b, amphiphysin IIb-1: p73b complex is
formed (100).
[S29] Formation of amphiphysin IIb-1: p73b complex results in relocalization of nuclear p73 in to cytoplasm, which is an
inhibitory eﬀect on p73’s TA function (100).
[S30] CTF2 interacts with p73at it the 228–312 residue range (78).
[S31] CTF2 suppresses the induction ability of p73 on p21 promoter (78).
[S32] E4orf6 is a viral protein and it can bind to the common C-terminal region of p73a and p73b (48,101).
[S33] E4orf6 downregulates the apoptotic activity of p73 (48,101).
[S34] Pirh2 interacts with p73 (102).
[S35] p73 binds to zinc ﬁnger region of WT1 (103).
[S36] WT1 can inhibit the transcription activity of p73 by direct binding. It speciﬁcally overcomes the stimulation eﬀect of p73
on MDM2 promoter (103).
(continued)
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nuclear bodies (A41). Chk1 targets the TA domains of p53
and p73 to improve the TA of p53 and p73. Chk2 med-
iates the posttranslational modiﬁcation of p53 and p73,
by direct and indirect means, respectively (40). Cyclin
G interacts both with p53 and p73, causing downregula-
tion of these proteins. (D19) The mechanisms diﬀer
such that the negative eﬀect of Cyclin G on p53 is
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[S37] PKA-Cb interacts with both N- and C-termini of p73 (104).
[S38] [S39] Bound PKA-Cb can catalyze phosphorylation of p73 (104).
[S40] One of the suppression mechanisms of p73’s transcriptional activity depends on the kinase activity of PKA-Cb (104).
[S41] SAM and ID inhibit the association of p300/CBP with p73 (105,106).
[S42] [S43] Cyclin A/B:Cdk1/2 complexes are essential components in cell cycle because they can induce progression in to another
phase in the cycle. If this complex is present, it can phosphorylate p73 on Thr86 (38,107).
[S44] If p73 is phosphorylated by Cyclin A/B:Cdk1/2 complexes, it can no longer induce cell cycle arrest or apoptosis, since the
cell is forced to end mitosis (38,107).
[S45] Tax associates with p300 (108,109).
[S46] YAP is phosphorylated at Ser127 (110).
[S47] Phosphorylation of YAP is mediated by Akt (110).
[S48] YAP can no longer stimulate the TA of activity of p73 if it is phosphorylated by Akt (85,110).
[S49] pRb and c-abl forms a complex (24,60).
[S50] In the cells which are in G0/G1 phase of mitosis, pRb binds to c-abl to interrupt the c-abl mediated signaling
cascade (24,60).
[S51] [S52] Similar to p53, DNp73 will be active after it forms a homo-tetramer (17,18,22).
[S53] Heterotetramers can be formed among p73 family members (17,18,22,111).
[S54] The activity of TAp73 is suppressed by DNp73 via two distinct mechanisms; either DN or TA isoforms competes for the
same DNA-binding sites, such as p21, MDM2 and 14-3-3s, or they form inactive heterotetramers (11,49).
Degradation
[D1] This edge represents the degradation of p73.
[D2] If p73 is recruited in to PML-NB complex it is going to be protected from proteosomal degradation (66).
[D3] c-Jun increases the stability of p73 by increasing its half-life. And this action prevents p73 from proteosomal
degradation (45).
[D4] Ubc9 catalyzes the interaction between SUMO-1 and p73 (98,112).
[D5] SUMO-1 mediated modiﬁcation recruits p73 in to proteosome (98).
[D6] Itch is a ligase and it can bind to p73’s PY motif via its WW domain (113).
[D7] p73 is ubiquitinated as a result of p73:Itch formation (113).
[D8] Itch promotes the ubiquitination of p73 (113).
[D9] Ubiquitinated p73 is rapidly degraded (113).
[D10] Cullin is modiﬁed by Nedd8 covalently (49,114).
[D11] Neddylated-Cullin:Roc1 ring is formed to establish the core module of E3 ubiquitin ligase (49,114).
[D12] [D13] When neddylated-Cullin:Roc1 is formed, p73 is exposed to ubiquitination (49,114).
[D14] The detection of ubiquitinated p73 residues leads to its degradation (49,114).
[D15] SAM domain of p73 is required for its interaction with UFD2a (115).
[D16] UFD2a stimulates the degradation of p73 without changing its ubiquitination levels (115).
[D17] NQO1 binds to SAM domain of p73 in a NADH-mediated manner (116).
[D18] The physical interaction between NQO1 and NADH hinders p73 degradation, which is controlled by 20S
proteosome (116).
[D19] Cyclin G and p73 are interacting proteins (117).
[D20] Cyclin G enhances degradation of p73 without implying any ubiquitinations on it (117).
[D21] [D210] [D22] The transcription of Cyclin G is enhanced by p73. So, basing on this fact, it would be logical to claim that there
is a negative feedback loop between p73 and Cyclin G (118).
Transcirptional activation
[T1] [T10] p73 binds to the promoters of various genes.
[T2] p73 induces the transcription of following genes; p21, Pig3, CD95, GADD45, p53AIP1, Noxa, Scotin, 14-3-3s, IGF-BP3,
GADD153/CHOP, Mdm2, Cyclin G, PUMA, Bax (13,17,19,41).
[T3] [T4] If the level of E2F1 is high, it can repress hTERT level directly (119).
[T5] [T50] [T6] hTERT core promoter can directly be activated by Sp1 (111,120).
[T7] p73 and Sp1 form a complex (111,120).
[T8] The association among p73 and Sp1 inhibits the formation of the Sp1:hTERT promoter complex (111,120).
[T9] [T90] [T10] E2F1 stimulates the transcription of Apaf-1 (51,121).
[T11] PUMA imposes a conformational modiﬁcation on Bax (122,123).
[T12] As a result of the modiﬁcation in its conformation, Bax is delocalized in to mitochondria (122,123).
[T13] Cytochrome c is released (122,123).
[T14] Release of cytochrome c is mediated by Bax translocation (122,123).
[T15] [T16] As the complex between Apaf1 and cytochrome c is formed, the mechanism for caspase cascade is triggered (122–124).
[T17] TAp73 can bind to DNp73 promoter (22,125).
[T18] One of the most important negative feedback loops in p73 network arises as TAp73 stimulates DNp73
transcription (22,125).
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14–3–3s, Gadd45, Bax, PUMA (41), (T2) are also trans-
activated by both p73 and p53.
MDM2 is a signiﬁcant protein in the p53 network, since
it mediates ubiquitination and degradation of p53 (42). It
is also associated with p73 by direct binding and instead of
its degradation, binding of MDM2 results in stabilization
of p73 (42), (S1). This binding also leads to the inactiva-
tion of p73, by disrupting the interaction between p73 and
p300/CBP (43). The tyrosine kinase, c-Abl stimulates
DNA binding by p53 through direct interaction, but it
stabilizes p73 by posttranslational modiﬁcation (24,44),
(A12). c-Jun stabilizes p73, increasing its pro-apoptotic
activity (A53), while it negatively regulates p53 (45).
Another protein having opposing aﬀects on p73 and p53
is CTF2. It enhances p53 activity but inhibits DNA bind-
ing to p73 (46), (S30).
There are also proteins that aﬀect p73 without having
any interaction with p53, such as NEDL2 (47), (A45);
MM1 (45), (A37); adenovirus protein E4orf6 (48), (S23)
and Itch, (D6). Among these proteins, Itch stands out as
being the protein having a role in the degradation of p73.
Itch functions in a manner similar to that of the MDM2 in
p53 network (47).
Hierarchical clustering candefine paths with small number
ofinteractions, butnot large functional categories
The interactions of the p73 MIM are deﬁned at a binary
level by two diﬀerent approaches. In the ﬁrst approach,
only direct (ﬁrst degree) physical interactions between pro-
teins are taken into consideration. The results were unable
to deﬁne meaningful clusters. They also excluded many
proteins, which are related to the network via contingen-
cies only. In the second approach, ﬁrst-degree contingen-
cies where the two proteins having an interaction deﬁned
by a contingency are also counted as binary interactions.
However, contingencies aﬀecting other contingencies
(higher degree) are not included.
As a result of the second approach, the clustering pro-
gram was able to deﬁne paths with small number of
interactions in the network, although large clusters corre-
sponding to functional categories could not be obtained
(See Supplementary material). For relatively small cate-
gories (Figure 2a), namely Transcriptional Activity and
Degradation, the proteins involved could mostly be distin-
guished in the hierarchical tree. The main pathway leading
to apoptosis in the Transcriptional Activation functional
category, starting from the PUMA and Bax transcription
(T2), and ending at the apoptosis box (T15) is deﬁned as a
branch, where Bax and PUMA have a closer relation,
merging with cytochrome c, Apaf-1 and the Apoptosis
box. In the case of the Degradation functional category,
the proteins inﬂuencing degradation of p73 by direct inter-
actions are also deﬁned as a branch including Cyclin G,
Cyclin G promoter, NQO1, UFD2a and the degradation
of p73. However, other members of this category which
lead to the degradation of p73 by covalent modiﬁcations
could not be mined from the given input information.
In the Suppression and Activation functional categories,
they ¨ 11 nodes—including theNp73 isoform and its
promoter—that aﬀect the p73 activity in the same path,
acting on T1, are well clustered. In addition to those men-
tioned clusters, there are also small groups (3–4 nodes) of
interrelated proteins placed in close relation in the hier-
archical tree, such as hTERT, hTERT promoter and Sp1.
DISCUSSION
Biologicalinformationontheinteractionsofp73areorganized
in thep73 MIM withspecial emphasis on domainspecificity
p73 has major roles in the embryonic diﬀerentiation and in
the tumor suppression networks. Due to the scarcity of
data, p73 interactions related to diﬀerentiation are not
considered in this work. Here, we focus on the apoptotic
function of p73. MIM notation (Figure 2b) is selected for
the network representation. We added some extensions for
the representation of domains (Figure 3) and isoforms.
The extensions which emphasize the domain speciﬁcity
made it possible to demonstrate whether an interaction
is valid for a speciﬁc p73 isoform of interest. The data
are stored in both human and computer readable formats
for ease of use in future studies.
The constructed p73 MIM organizes the information
related to the biology of the p73. While constructing the
map, special attention was paid to the domain speciﬁcity
of the p73 interactions. This feature makes the p73 MIM
distinguishable as compared with other PPI maps. The
organization of the 53 nodes and 176 edges of the p73
MIM into ﬁve functional categories provide a clear and
compact representation of the biological mechanisms
related to p73 function.
Functional categories demonstrate biologically
significant interrelations
The functional categories identiﬁed from the nodes and
edges of the p73 MIM provide a compact structure of
the network, yielding ﬁve functional groups, Upregulation,
Activation, Suppression, Degradation, Transcriptional Acti-
vation and their interrelationships.
The Upregulation and Activation categories are related
via the node E2F1 of the Upregulation category, and the
major pathway for p73 activation (A54/U11). When ATM
(A1–7) is activated after DNA damage, it activates the
stimulators of p73 (A8) and E2F1 (U2). In turn, E2F1
increases the activity of ATM (U11), forming a positive
feedback loop. This loop is biologically signiﬁcant and it
can be followed from the p73 MIM. The PML-NB:p73
complex and c-Jun can inhibit the degradation of
p73 (D2-3), relating the Activation and Degradation func-
tional categories. Furthermore, recruitment of p73 into
PML-NBs complements paths, which are stimulated by
ATM upon recognition of DNA damage (A3). The exis-
tence of the interactions in diﬀerent paths initiated by the
same signal, DNA damage in this case, demonstrates the
robust structure of this biological network.
In the Suppression functional category, instead of form-
ing complex pathways for p73 suppression, the proteins
mostly bind directly to p73 or inhibit the interactions that
activate p73. When p73 is no longer required for the cell
activity, it is degraded via sumoylation (D4–5, S22),
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proteins such as UFD2a or Cyclin G (D16–20) which may
not need proteasomal activity. The Transcriptional
Activation and the Upregulation functional categories
are related via the activation of the Apaf-1 promoter by
E2F1 (T3).
Through the map, we observe numerous paths for p73
degradation, and a rather simple composition for interac-
tions relating to p73 suppression. p73 is kept at very low
concentrations when there is no DNA damage (49), which
demonstrates the biological priority of the degradation
invoked by the suppression mechanism. Here, we illustrate
that the structure of the Suppression and Degradation
functional categories in the p73 network correlates with
this biological preference.
Anticoherent interactions of thep73 MIM suggestfurther
experimental investigation
Construction of the interaction networks allows identiﬁca-
tion of the regions where there are inconsistencies in the
functions of proteins. By tracing the interaction paths, we
point out two nodes, pRB and c-Jun, which are anticoher-
ent in their tasks in the p73 MIM. pRB is considered as
anticoherent, since it regulates p73 both negatively and
positively, by suppressing the activities of E2F1 and
RACK1 (U17–18, S17), respectively. c-Jun has strong
eﬀects on the positive regulation of p73, by repressing its
degradation and stimulating its transcriptional activity
(D3). In contrast to these positive eﬀects, transcription
of MDM2, a p73 suppressor, is also stimulated by c-Jun
(S8). Furthermore, those two anticoherent nodes are inter-
related: pRB binds to the promoter of c-Jun and enhances
its transcription (A56–57).
The observed apparent inconsistency in the p73 net-
work for pRB and c-Jun may indicate the existence of
interactions at diﬀerent spatial or temporal cell states,
an experimental misidentiﬁcation or missing data regard-
ing these proteins. Either way, based on our analysis of the
p73 interaction network, we propose that the pathways
involving pRB and c-Jun, should be further explored
experimentally to clarify the regulatory mechanisms in
p73 network.
Comparison of thep73 MIM and thep53 network presents
similarities and differences inthe interactions
The compared nodes of the p73 MIM and of the p53
network can be classiﬁed into four categories: proteins
(i) with the same eﬀects in both networks; (ii) with similar
eﬀects on p73 and p53 via diﬀerent mechanisms; (iii) with
diﬀerent, or in some cases, opposing roles in the networks
and (iv) existing in the p73 network which have no eﬀect
on p53, as explained in the Results section. This classiﬁca-
tion indicates that p73 and p53 can use parallel or alter-
nate interactions leading to apoptosis.
Eleven nodes are shared by the networks of p73 and
p53. This fact emphasizes the crucial importance of p73
in cancer research. The common pathways also indicate
that tumor formation caused by malfunctioning of the
shared proteins could aﬀect both p53 and p73, and that
p73 could be an alternative tumor suppressor in cases of
cancer formation related to p53 mutations. Finally, they
indicate a competition between p73 and p53 in cases where
they target the same promoters. Furthermore, proteins
that do not exist in the p53 network and are related to
the transcription mechanism of p73 can be good candi-
dates for further research, since proteins related to the
transcription of p73 have important roles in both activa-
tion and inhibition of apoptosis pathways.
Pathways withfewer interactions areextracted from the
network by hierarchical clustering withintroduction of
first-degree contingencies
For cross-validating the manually organized functional
categories, the p73 MIM is analyzed by a clustering algo-
rithm, using two diﬀerent input matrices. The ﬁrst
approach, which excluded the contingencies, was unable
to deﬁne the paths of the network. In the second
approach, which included both the ﬁrst-degree physical
interactions and the ﬁrst-degree contingencies, the large
categories, e.g. Activation cannot be thoroughly extracted
from the network. These categories include many high-
order contingencies; more importantly, common ending
points of the pathways are mostly contingencies.
However, via the additional information present in the
second approach, nodes which construct pathways with
small number of interactions can be clustered together
and most members of small functional categories can be
extracted. This improvement suggests that by using a
proper representation of the MIM notation in a computer
readable format, computer-based analyses can supply
information. Such knowledge can be used for improve-
ment of the maps, assisting in the construction of func-
tional categories.
Tracing the edges of the map and considering the results
of the network analysis will provide an organized way to
review and analyze the underlying apoptosis machinery of
p73. Such a study of p73 is essential both for experimen-
talists and theoreticians working with p73 or proteins in
its network. Clearly, pointing to speciﬁc regions in the
network may help in avoiding some misleading eﬀects
which are the outcome of the sparse data, an evident
fact in cancer research.
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